CliffBio
small molecule

PRADAXA

DABIGATRAN ETEXILATE MESYLATE

Loss of exclusivityMarch 2026latest FDA-listed patent expiry
CompanyBoehringer Ingelheim →See this company's full patent-cliff portfolio

Drug detail

Brand namePRADAXA
Active ingredientDABIGATRAN ETEXILATE MESYLATE
StrengthEQ 40MG BASE/PACKET
Dosage formPELLETS
RouteORAL
ModalitySmall molecule
FDA approvalJune 2021
Marketing statusRX

Listed patents

PatentExpiresType
7932273*PEDMarch 2026—
7932273September 2025substance, product

More from Boehringer Ingelheim

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

PRADAXA patent cliff — loss of exclusivity March 2026 | CliffBio